JP2019142823A5 - - Google Patents

Download PDF

Info

Publication number
JP2019142823A5
JP2019142823A5 JP2018030208A JP2018030208A JP2019142823A5 JP 2019142823 A5 JP2019142823 A5 JP 2019142823A5 JP 2018030208 A JP2018030208 A JP 2018030208A JP 2018030208 A JP2018030208 A JP 2018030208A JP 2019142823 A5 JP2019142823 A5 JP 2019142823A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
group
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018030208A
Other languages
English (en)
Japanese (ja)
Other versions
JP7223502B2 (ja
JP2019142823A (ja
JP7223502B6 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2018030208A priority Critical patent/JP7223502B6/ja
Priority claimed from JP2018030208A external-priority patent/JP7223502B6/ja
Priority to PCT/JP2019/006780 priority patent/WO2019163943A1/ja
Publication of JP2019142823A publication Critical patent/JP2019142823A/ja
Publication of JP2019142823A5 publication Critical patent/JP2019142823A5/ja
Publication of JP7223502B2 publication Critical patent/JP7223502B2/ja
Application granted granted Critical
Publication of JP7223502B6 publication Critical patent/JP7223502B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018030208A 2018-02-22 2018-02-22 医薬組成物 Active JP7223502B6 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2018030208A JP7223502B6 (ja) 2018-02-22 2018-02-22 医薬組成物
PCT/JP2019/006780 WO2019163943A1 (ja) 2018-02-22 2019-02-22 医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018030208A JP7223502B6 (ja) 2018-02-22 2018-02-22 医薬組成物

Publications (4)

Publication Number Publication Date
JP2019142823A JP2019142823A (ja) 2019-08-29
JP2019142823A5 true JP2019142823A5 (cg-RX-API-DMAC7.html) 2021-01-14
JP7223502B2 JP7223502B2 (ja) 2023-02-16
JP7223502B6 JP7223502B6 (ja) 2024-02-08

Family

ID=67688423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018030208A Active JP7223502B6 (ja) 2018-02-22 2018-02-22 医薬組成物

Country Status (2)

Country Link
JP (1) JP7223502B6 (cg-RX-API-DMAC7.html)
WO (1) WO2019163943A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111333659B (zh) * 2019-09-19 2021-04-06 杭州科兴生物化工有限公司 一类星孢菌素类衍生物及其制备方法和应用
CN116407555A (zh) * 2023-01-18 2023-07-11 北京大学 Egfr蛋白磷酸化的抑制试剂及抑制方法和用途
CN116041371B (zh) * 2023-01-29 2024-04-19 杭州科兴生物化工有限公司 7-羰基星孢菌素衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501526A (ja) * 1994-06-01 1998-02-10 チバ−ガイギー アクチェンゲゼルシャフト 多薬物耐性に対する作用物質としてのカルバゾール誘導体
KR101379693B1 (ko) 2005-08-25 2014-04-10 크리어빌리스 쎄라퓨틱스 에스.피.에이. K-252a 및 그의 유도체의 중합체 컨쥬게이트
US10220026B2 (en) 2014-08-11 2019-03-05 The University Of Tokyo Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer
EP3505555B1 (en) * 2016-08-23 2024-01-03 Kawasaki Institute of Industrial Promotion Polymer, method for producing polymer, and drug conjugate

Similar Documents

Publication Publication Date Title
JP2018517686A5 (cg-RX-API-DMAC7.html)
JP2020535173A5 (cg-RX-API-DMAC7.html)
JP2022520061A5 (cg-RX-API-DMAC7.html)
JP2020514311A5 (cg-RX-API-DMAC7.html)
JP2018526376A5 (cg-RX-API-DMAC7.html)
JP2015508103A5 (cg-RX-API-DMAC7.html)
EP3703755B1 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer
JP5892565B2 (ja) 増殖性疾患を治療するためのサパシタビンの使用
JP2009505980A5 (cg-RX-API-DMAC7.html)
TW201924720A (zh) Parp抑制劑用於治療化療耐藥的卵巢癌或乳腺癌的用途
WO2023035223A1 (zh) 药物组合物及其用途
JP2021169534A (ja) 化学療法の改善
IL274919B2 (en) Albumin-binding prodrugs of auristatin E derivatives
JP2021523169A (ja) ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
KR20140129164A (ko) 히스톤 데아세틸라아제 억제제 및 파조파닙의 조합물 및 이의 용도
EP1868435A2 (en) Combinations, methods and compositions for treating cancer
JP2023505687A (ja) 癌の処置方法
WO2022051491A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
RU2007145932A (ru) Способ лечения устойчивого к лекарственным средствам рака
US20160120848A1 (en) Specific cancer treatment regimes with ganetespib
KR20240040768A (ko) 암의 치료에 사용하기 위한 1-(4-{[4-(디메틸아미노)피페리딘-1-일]카르보닐}페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물
JP2005510471A (ja) 減少した毒性のシスプラチン製剤及びそれを使用する方法
JP2026508792A (ja) 結晶形態、医薬組成物、及びその使用方法
KR20080048488A (ko) Dmxaa를 포함하는 암 치료용 조합물
WO2013137433A1 (ja) 3剤を組み合わせた新規な抗腫瘍剤